Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study

被引:199
作者
Renoux, Christel [1 ,2 ,3 ]
Dell'Aniello, Sophie [1 ,2 ,3 ]
Garbe, Edeltraut [4 ]
Suissa, Samy [1 ,2 ,3 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Ctr Clin Epidemiol, McGill Pharmacoepidemiol Res Unit, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3T 1E2, Canada
[3] McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada
[4] Univ Bremen, Dept Clin Epidemiol, Bremen Inst Prevent Res & Social Med, D-28359 Bremen, Germany
来源
BMJ-BRITISH MEDICAL JOURNAL | 2010年 / 340卷
基金
加拿大健康研究院;
关键词
PRACTICE RESEARCH DATABASE; POSTMENOPAUSAL WOMEN; VENOUS THROMBOEMBOLISM; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CONTROLLED-TRIAL; EQUINE ESTROGEN; METAANALYSIS; ASSOCIATION; IMPACT;
D O I
10.1136/bmj.c2519
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To determine the risk of stroke associated with oral and transdermal routes of administration of hormone replacement therapy. Design Population based nested case-control study. Setting About 400 general practices in the United Kingdom contributing to the General Practice Research Database. Participants Cohort of all women in the database aged 50-79 years between 1 January 1987 and 31 October 2006 who were members of a practice that fulfilled predefined quality criteria and without a diagnosis of stroke before cohort entry. For each case of stroke occurring during follow-up, up to four controls were selected from among the cohort members in the risk sets defined by the case. Exposure to hormone replacement therapy (HRT) was categorised into oestrogens only, oestrogens plus progestogen, progestogen only, and tibolone. Oestrogens were further subdivided according to the route of administration (oral v transdermal) and dose (high v low). Main outcome measures Rate ratio of stroke associated with current use of oral and transdermal HRT compared with no use. Current use was considered as a prescription whose duration included the index date. Results There were 15 710 cases of stroke matched to 59 958 controls. The rate of stroke in the cohort was 2.85 per 1000 per year. The adjusted rate ratio of stroke associated with current use of transdermal HRT was 0.95 (95% CI 0.75 to 1.20) relative to no use. The risk of stroke was not increased with use of low oestrogen dose patches (rate ratio 0.81(0.62 to 1.05)) compared with no use, whereas the risk was increased with high dose patches (rate ratio 1.89 (1.15 to 3.11)). Current users of oral HRT had a higher rate of stroke than non-users (rate ratio 1.28 (1.15 to 1.42)) with both low dose and high dose. Conclusions The use of transdermal HRT containing low doses of oestrogen does not seem to increase the risk of stroke. The presence of residual confounding, however, cannot be entirely excluded in the interpretation of this finding.
引用
收藏
页数:7
相关论文
共 32 条
[1]   Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke - A nested case-control study [J].
Andersohn, Frank ;
Schade, Rene ;
Suissa, Samy ;
Garbe, Edeltraut .
STROKE, 2006, 37 (07) :1725-1730
[2]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[3]   Hormone therapy and cerebrovascular events:: a population-based nested case-control study [J].
Arana, Alejandro ;
Varas, Cristina ;
Gonzalez-Perez, Antonio ;
Gutierrez, Lia ;
Bjerrum, Lars ;
Garcia Rodriguez, Luis A. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (05) :730-736
[4]   Percutaneous 17β-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women [J].
Archer, DF .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2003, 10 (06) :516-521
[5]   Association between hormone replacement therapy and subsequent stroke: a meta-analysis [J].
Bath, PMW ;
Gray, LJ .
BRITISH MEDICAL JOURNAL, 2005, 330 (7487) :342-344A
[6]   Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study [J].
Canonico, M. ;
Oger, E. . ;
Conard, J. . ;
Meyer, G. ;
Levesque, H. ;
Trillot, N. ;
Barrellier, M. T. . ;
Wahl, D. ;
Emmerich, J. . ;
Scarabin, P. Y. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (06) :1259-1265
[7]   Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis [J].
Canonico, Marianne ;
Plu-Bureau, Genevieve ;
Lowe, Gordon D. O. ;
Scarabin, Pierre-Yves .
BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7655) :1227-+
[8]   Hormone therapy and venous thromboembolism among postmenopausal women -: Impact of the route of estrogen administration and progestogens:: The ESTHER study [J].
Canonico, Marianne ;
Oger, Emmanuel ;
Plu-Bureau, Genevieve ;
Conard, Jacqueline ;
Meyer, Guy ;
Levesque, Herve ;
Trillot, Nathalie ;
Barrellier, Marie-Therese ;
Wahl, Denis ;
Emmerich, Joseph ;
Scarabin, Pierre-Yves .
CIRCULATION, 2007, 115 (07) :840-845
[9]  
Cherry N, 2002, LANCET, V360, P2001
[10]  
Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x